Excellent response of cetuximab plus chemotherapy after pembrolizumab monotherapy in metastatic hypopharyngeal cancer: A case report
Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) typically have an unfavorable prognosis, with a median survival of only 6 to 15 months in most studies. In cases other than local relapse or oligometastases, systemic therapy plays the dominant role. The choice of re...
Saved in:
| Main Authors: | Anh Tuan Pham, Thang Huu Nguyen, Thai Hong Le, Toan Khanh Phan, Anh Phuong Nguyen, Ngoc Minh Le, Thao Thu Vu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621924000607 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A retrospective efficacy and safety study of pembrolizumab/cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancer
by: Guangnan Yao, et al.
Published: (2025-06-01) -
Continuous remission of single-mode therapy with pembrolizumab plus chemotherapy in locally advanced hypopharyngeal carcinoma: a case report
by: Guoning Yu, et al.
Published: (2025-06-01) -
Surgical management of hypopharyngeal cancer (narrative review)
by: N. N. Radzhabova, et al.
Published: (2019-07-01) -
Indian clinical practice consensus guidelines for the management of locoregional hypopharyngeal cancer - Update 2023
by: HS Darling, et al.
Published: (2024-11-01) -
Real world treatment patterns for recurrent and metastatic head and neck cancer in the post-KEYNOTE 048 era
by: Daniel Y. Lee, et al.
Published: (2025-05-01)